Article
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Endocrinology - 1 Apr 2004
Agostini Maura, Gurnell Mark, Savage David B, Wood Emily M, Smith Aaron G, Rajanayagam Odelia, Garnes Keith T, Levinson Sidney H, Xu H Eric, Schwabe John W R, Willson Timothy M, O'Rahilly Stephen, Chatterjee V Krishna
Abstract excerpt
Loss-of-function mutations in the ligand-binding domain of human peroxisome proliferator-activated receptor gamma (PPARgamma) are associated with a novel syndrome characterized by partial lipodystrophy and severe insulin resistance. Here we have further characterized the properties of natural dominant-negative PPARgamma mutants (P467L, V290M) and evaluated the efficacy of putative natural ligands and synthetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.